Pegylated liposomal doxorubicin: an efficient treatment in patients with Hodgkin lymphoma relapsing after high dose therapy and stem cell transplation.

MLA

Clozel, Thomas, et al. “Pegylated Liposomal Doxorubicin: An Efficient Treatment in Patients with Hodgkin Lymphoma Relapsing after High Dose Therapy and Stem Cell Transplation.” British Journal of Haematology, vol. 162, no. 6, Sept. 2013, pp. 846–48. EBSCOhost, https://doi.org/10.1111/bjh.12428.

APA

Clozel, T., Deau, B., Benet, C., Franchi, P., Robin, M., Madelaine, I., Thieblemont, C., Kerviler, E., Brière, J., & Brice, P. (2013). Pegylated liposomal doxorubicin: an efficient treatment in patients with Hodgkin lymphoma relapsing after high dose therapy and stem cell transplation. British Journal of Haematology, 162(6), 846–848. https://doi.org/10.1111/bjh.12428

Chicago

Clozel, Thomas, Benedicte Deau, Claire Benet, Patricia Franchi, Marie Robin, Isabelle Madelaine, Catherine Thieblemont, Eric Kerviler, Josette Brière, and Pauline Brice. 2013. “Pegylated Liposomal Doxorubicin: An Efficient Treatment in Patients with Hodgkin Lymphoma Relapsing after High Dose Therapy and Stem Cell Transplation.” British Journal of Haematology 162 (6): 846–48. doi:10.1111/bjh.12428.